Due to a production error, the “Conflict of Interest” statement incorrectly stated that “WL was a full-time” instead of “WL is a full-time.”
The corrected section should read:
“WL is a full-time executive employee of Regeneron Pharmaceuticals, Tarrytown, NY, United States.”
The publisher apologizes for this mistake. The original version of this article has been updated.
Summary
Keywords
pain, spinal cord dorsal horn, KCC2, Kcc2 gene expression enhancer, GSK3, delta-catenin, Kaiso
Citation
Frontiers Production Office (2022) Erratum: Long March Toward Safe and Effective Analgesia by Enhancing Gene Expression of Kcc2: First Steps Taken. Front. Mol. Neurosci. 15:979385. doi: 10.3389/fnmol.2022.979385
Received
27 June 2022
Accepted
27 June 2022
Published
05 July 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
15 - 2022
Updates
Copyright
© 2022 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office production.office@frontiersin.org
This article was submitted to Pain Mechanisms and Modulators, a section of the journal Frontiers in Molecular Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.